Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
Background. In this retrospective study, we compared the efficacy of tacrolimus (TAC) or prednisolone (PSL) for maintenance therapy in patients with ulcerative colitis (UC) at remission. Methods. The study patients were followed up for at least one year after induction of remission with either PSL (...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/5956316 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552182285598720 |
|---|---|
| author | Ayumi Ito Bunei Iizuka Teppei Omori Shinichi Nakamura Katsutoshi Tokushige |
| author_facet | Ayumi Ito Bunei Iizuka Teppei Omori Shinichi Nakamura Katsutoshi Tokushige |
| author_sort | Ayumi Ito |
| collection | DOAJ |
| description | Background. In this retrospective study, we compared the efficacy of tacrolimus (TAC) or prednisolone (PSL) for maintenance therapy in patients with ulcerative colitis (UC) at remission. Methods. The study patients were followed up for at least one year after induction of remission with either PSL (n=55, between April 2004 and March 2014) or TAC (n=40, between April 2009 and March 2014). The clinical features and relapse rates were compared in the two groups. Maintenance therapy in the TAC group included TAC alone, AZA alone, and TAC plus AZA. Results. The recurrence rates at 1500 days after remission were 61% and 46% for the PSL and TAC groups, respectively (P<0.05). The recurrence rates at 600 days for TAC, AZA, and TAC + AZA maintenance groups were 24%, 49%, and 55%, respectively. Nephrotoxicity developed in 16 patients on TAC maintenance therapy. Conclusions. TAC monotherapy is a potential alternative especially for PSL nonresponders or those intolerant to AZA. However, patients on TAC therapy should be regularly monitored for adverse effects including nephrotoxicity. |
| format | Article |
| id | doaj-art-c3b63eaa42ec486fabca8a07da06df69 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-c3b63eaa42ec486fabca8a07da06df692025-02-03T05:59:22ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/59563165956316Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation StudyAyumi Ito0Bunei Iizuka1Teppei Omori2Shinichi Nakamura3Katsutoshi Tokushige4Department of Gastroenterology, Tokyo Women’s Medical University, Kawada-cho 8-1, shinjuku-ku, Tokyo 162-8666, JapanDepartment of Gastroenterology, Tokyo Women’s Medical University, Kawada-cho 8-1, shinjuku-ku, Tokyo 162-8666, JapanDepartment of Gastroenterology, Tokyo Women’s Medical University, Kawada-cho 8-1, shinjuku-ku, Tokyo 162-8666, JapanDepartment of Gastroenterology, Tokyo Women’s Medical University, Kawada-cho 8-1, shinjuku-ku, Tokyo 162-8666, JapanDepartment of Gastroenterology, Tokyo Women’s Medical University, Kawada-cho 8-1, shinjuku-ku, Tokyo 162-8666, JapanBackground. In this retrospective study, we compared the efficacy of tacrolimus (TAC) or prednisolone (PSL) for maintenance therapy in patients with ulcerative colitis (UC) at remission. Methods. The study patients were followed up for at least one year after induction of remission with either PSL (n=55, between April 2004 and March 2014) or TAC (n=40, between April 2009 and March 2014). The clinical features and relapse rates were compared in the two groups. Maintenance therapy in the TAC group included TAC alone, AZA alone, and TAC plus AZA. Results. The recurrence rates at 1500 days after remission were 61% and 46% for the PSL and TAC groups, respectively (P<0.05). The recurrence rates at 600 days for TAC, AZA, and TAC + AZA maintenance groups were 24%, 49%, and 55%, respectively. Nephrotoxicity developed in 16 patients on TAC maintenance therapy. Conclusions. TAC monotherapy is a potential alternative especially for PSL nonresponders or those intolerant to AZA. However, patients on TAC therapy should be regularly monitored for adverse effects including nephrotoxicity.http://dx.doi.org/10.1155/2016/5956316 |
| spellingShingle | Ayumi Ito Bunei Iizuka Teppei Omori Shinichi Nakamura Katsutoshi Tokushige Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study Gastroenterology Research and Practice |
| title | Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study |
| title_full | Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study |
| title_fullStr | Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study |
| title_full_unstemmed | Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study |
| title_short | Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study |
| title_sort | tacrolimus for remission induction and maintenance therapy in patients with ulcerative colitis a retrospective evaluation study |
| url | http://dx.doi.org/10.1155/2016/5956316 |
| work_keys_str_mv | AT ayumiito tacrolimusforremissioninductionandmaintenancetherapyinpatientswithulcerativecolitisaretrospectiveevaluationstudy AT buneiiizuka tacrolimusforremissioninductionandmaintenancetherapyinpatientswithulcerativecolitisaretrospectiveevaluationstudy AT teppeiomori tacrolimusforremissioninductionandmaintenancetherapyinpatientswithulcerativecolitisaretrospectiveevaluationstudy AT shinichinakamura tacrolimusforremissioninductionandmaintenancetherapyinpatientswithulcerativecolitisaretrospectiveevaluationstudy AT katsutoshitokushige tacrolimusforremissioninductionandmaintenancetherapyinpatientswithulcerativecolitisaretrospectiveevaluationstudy |